Shares of Heron Therapeutics Inc. HRTX, -5.31% gained 3.0% in trading on Thursday after the company said the Food and Drug Administration had approved its non-opioid anesthetic for use in some surgical patients. The drug, Zynrelef, is expected to become available to hospitals in July. Heron’s stock is down 16.2% for the year, while the S&P 500 SPX, +1.24% is up 8.1%.
View Article Origin Here
